Radiation Safety Considerations with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)

Seminars in Nuclear Medicine

Volumn 34, Issue 1 SUPPL.1, 2004, Pages 20-23

  Zhu, Xiaowei ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID; IBRITUMOMAB TIUXETAN;

BETA RADIATION; CYTOTOXICITY; DRUG ELIMINATION; FAMILY; GAMMA RADIATION; HUMAN; NONHODGKIN LYMPHOMA; OUTPATIENT; RADIATION BEAM; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIATION FIELD; RADIATION INJURY; RADIATION MONITORING; RADIATION SHIELD; RADIOIMMUNOTHERAPY; REVIEW; SAFETY; TUMOR LOCALIZATION; URINALYSIS;

EID: 0842303402     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2003.11.005     Document Type: Article

References (11)

1. Zevalin (ibritumomab tiuxetan) prescribing information: IDEC Pharmaceuticals Corporation, San Diego, CA, 2002
2. Siegel JA, Zimmerman BE, Kodimer K, et al: A single dose calibrator dial setting accurately measures 90Y ibritumomab tiuxetan activity. J Nucl Med 44:317P, 2003 (suppl; abstr 1137)
3. Bexxar (tositumomab and iodine 131 tositumomab) prescribing information: Seattle, WA, Corixa Corporation, 2003
4. Kuzel TM, Rosen ST: Radioimmunotherapy of lymphomas and leukemias, in Henkin RE, Boles MA, Dillehay GL, Halama A, Zimmer M (eds): Nuclear Medicine. Vol 1. St Louis, MO, Mosby-Year Book, 1996, pp 584-600
5. Wootton R: Radiation Protection of Patients. Cambridge University Press, Cambridge, England, 1993
6. Delacroix D, Guerre JP, Leblanc P, et al: Radiation protection dosimetry, in: Radionuclide and Radiation Data Handbook. Vol 76, Nos. 1-2. Ashford, UK, Nuclear Technology Publishing, 1998, p 68
7. Zimmer M: Effectiveness of specific vial and syringe shields in reducing radiation exposure from 90Y Zevalin. J Nucl Med 43:45P, 2002 (abstr 164)
8. Zanzonico PB, Binkert BL, Goldsmith SJ: Bremsstrahlung radiation exposure from pure β-ray emitters. J Nucl Med 40:1024-1028, 1999
9. Wiseman G, Leigh B, Witzig T, et al: Radiation exposure is very low to the family members of patients treated with yttrium-90 Zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med 28:1198, 2001 (abstr)
10. Wiseman GA, Leigh BR, Erwin WD: Urinary clearance of 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin's lymphoma. J Nucl Med 42:268P, 2001 (suppl; abstr)
11. Wiseman GA, White CA, Stabin M, et al: Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 27:766-777, 2000